Sysmex Inostics Announces Key Clinical Data to be Presented at ASCO Annual Meeting 2016 - Abstract will be Included in the Best of ASCO® Program

CHICAGO, May 25, 2016 /PRNewswire/ --

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that the company and its collaborators will present key performance data of its OncoBEAM^® RAS CRC kit during an poster session at the ASCO Annual Meeting 2016 taking place June 3-7 in Chicago. The selected data further strengthens the growing body of evidence in support of integrating the blood-based OncoBEAM^® RAS CRC test into clinical practice as a viable alternative for determining eligibility of CRC patients for targeted anti-EGFR therapy.

Moreover, the respective abstract (#11538 "Performance of standardized BEAMing platform for detecting RAS mutations in the blood of metastatic colorectal cancer (mCRC) patients") has been hand selected to be included in the Best of ASCO^® program, which will be held this summer following the ASCO Annual Meeting. According to ASCO, the Best of ASCO^® is an educational initiative that condenses highlights from ASCO's Annual Meeting to increase global access to cutting-edge science selecting abstracts that reflect research that is relevant and significant in oncology today. In addition to three domestic Best of ASCO^® Meetings, there will also be nearly twenty international and officially licensed Best of ASCO^® Meetings.

The study included 238 mCRC patients recruited at centers in the US and Europe and revealed a high degree of concordance of the blood-based OncoBEAM^® RAS CRC kit with 222 of 238 (93.3% Overall Agreement) cases having equivalent RAS mutation status as that determined from tumor tissue. Additionally, data from Vidal et al. shows that plasma ctDNA may have utility in monitoring patients experiencing relapse, as the detection of emergence/disappearance of mutations may be indicative of response to targeted therapy.

"The new data presented at ASCO emphasize the value of our OncoBEAM^® RAS CRC kit and reinforce our commitment to improving the quality of treatment decisions for cancer patients around the world", said Frederick S. Jones, Ph.D., Director of Medical Scientific Affairs at Sysmex Inostics.

 Meeting abstracts are available at http://abstracts.asco.org/

Studies Presented at ASCO on OncoBEAM^® include:

1. Performance of standardized BEAMing platform for detecting RAS mutations in the blood of metastatic colorectal cancer (mCRC) patients  
     Frederick S. Jones et al.

Session Date and Time: 6/06/16, 1:00-4:30 

2. Plasma RAS mutations for the selection and monitoring of colorectal cancer patients treated with anti-EGFRtherapy
     Joana Vidal et al.

About Sysmex Inostics 

Sysmex Inostics, a subsidiary of Sysmex Corporation, is a molecular diagnostic company whose core competency is mutation detection in blood through highly sensitive molecular methods. Our OncoBEAM^® blood-based tests deliver a minimally invasive alternative for sensitive real time molecular diagnostics to improve cancer characterization and treatment.

Sysmex Inostics is a trusted partner to leading pharmaceutical companies, advancing their efforts to bring the most effective personalized cancer therapies to global markets. Sysmex Inostics companion diagnostics (CDx) team offers services for the development of non-invasive cell-free DNA-based IVD tests supported by a growing network of partners to cover the entire IVD development process.

Sysmex Inostics' headquarters and Service Laboratory are located in Hamburg, Germany; Sysmex Inostics' Clinical Laboratory is located in Baltimore, Maryland. For more information on OncoBEAM^® blood testing and the BEAMing technology refer to http://www.sysmex-inostics.com or email info@sysmex-inostics.com .

Contact:
Friederike Lehmann
Sysmex Inostics GmbH
Phone +49-(0)40-325907-0
Fax +49-(0)40-325907-6511
lehmann.friederike@sysmex-inostics.com